Internal Medicine

Tirzepatide outperforms insulin lispro in treating type 2 diabetes

In a Phase 3b clinical trial involving 1428 adults with type 2 diabetes already on basal insulin, tirzepatide, administered as a once-weekly subcutaneous injection, demonstrated significant advantages over prandial thrice-daily insulin lispro. Tirzepatide resulted in a substantial reduction in HbA1c levels, greater weight loss, and a higher percentage of participants...